RxDoctor Payments Data

Ajay Koshy, MD

Family Medicine · Bedford, NHNPI 1932184603

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,289 of the $5,827 with a category attached, or 90.8%. AbbVie accounts for 93.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $2,776 and has fallen 98.5% since, to $42 in 2025. Among family medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,827in general payments, 2019–2025

Across 24 payments — averaging $242.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Novo Nordisk$198
  • Medtronic$102
  • Merz North America, Inc.$63

What the payments were for

  • Speaking & faculty fees$5,28991%
  • Food & beverage$5379%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)15$5,463
Novo Nordisk7$198
Medtronic1$102
Merz North America, Inc.1$63

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,827 in reported general payments places this provider in the 95th percentile of 397 family medicine providers in New Hampshire.

See all family medicine providers in New Hampshire

Medicare billing

Part B allowed, 2024
$214,456
Medicare patients
545
Services billed
2,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide85$109,009
EliquisApixaban85$84,014
JardianceEmpagliflozin56$55,023
OzempicSemaglutide42$53,165
JanuviaSitagliptin Phosphate23$23,356
Synjardy XrEmpagliflozin/Metformin Hcl14$21,223
MyrbetriqMirabegron20$18,295
Breo ElliptaFluticasone/Vilanterol28$15,727
Combivent RespimatIpratropium/Albuterol Sulfate13$9,421
Janumet XrSitagliptin Phos/Metformin Hcl13$6,646
SymbicortBudesonide/Formoterol Fumarate12$5,218
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$3,962
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,888
Wixela InhubFluticasone Propion/Salmeterol22$2,964
Verapamil Er PmVerapamil Hcl12$2,824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$198$53,16542 claims
AbbVieSynthroid$5,463$1,57035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 397 family medicine providers in New Hampshire.

Other family medicine in Bedford

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →